Geode Capital Management LLC boosted its position in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 1.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,051,806 shares of the medical research company's stock after buying an additional 36,136 shares during the period. Geode Capital Management LLC owned 2.38% of NeoGenomics worth $45,022,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp increased its stake in shares of NeoGenomics by 1.6% during the third quarter. State Street Corp now owns 4,958,582 shares of the medical research company's stock worth $73,139,000 after acquiring an additional 80,449 shares during the period. First Light Asset Management LLC boosted its holdings in NeoGenomics by 14.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,782,561 shares of the medical research company's stock valued at $52,464,000 after purchasing an additional 480,396 shares in the last quarter. Dimensional Fund Advisors LP increased its position in NeoGenomics by 7.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,324,624 shares of the medical research company's stock worth $46,108,000 after purchasing an additional 217,687 shares during the period. American Century Companies Inc. raised its stake in shares of NeoGenomics by 5.4% during the 2nd quarter. American Century Companies Inc. now owns 3,261,756 shares of the medical research company's stock worth $45,241,000 after buying an additional 167,145 shares in the last quarter. Finally, Segall Bryant & Hamill LLC lifted its holdings in shares of NeoGenomics by 67.0% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 1,893,407 shares of the medical research company's stock valued at $27,928,000 after buying an additional 759,524 shares during the period. Hedge funds and other institutional investors own 98.50% of the company's stock.
In other news, General Counsel Alicia C. Olivo sold 5,175 shares of NeoGenomics stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $15.36, for a total value of $79,488.00. Following the transaction, the general counsel now owns 37,129 shares of the company's stock, valued at $570,301.44. This trade represents a 12.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.
NEO has been the subject of a number of research analyst reports. Benchmark reaffirmed a "buy" rating and issued a $18.00 target price on shares of NeoGenomics in a report on Tuesday, September 24th. Bank of America lifted their price objective on NeoGenomics from $18.00 to $19.00 and gave the stock a "neutral" rating in a report on Friday, December 13th. Needham & Company LLC reissued a "buy" rating and issued a $19.00 target price on shares of NeoGenomics in a report on Wednesday, November 6th. Finally, Jefferies Financial Group initiated coverage on NeoGenomics in a research note on Tuesday, December 10th. They set a "buy" rating and a $22.00 price target for the company. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, NeoGenomics has an average rating of "Moderate Buy" and an average price target of $20.30.
Check Out Our Latest Report on NeoGenomics
NASDAQ NEO opened at $16.53 on Tuesday. The firm's 50 day moving average price is $15.80 and its two-hundred day moving average price is $15.29. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of -27.10 and a beta of 1.24. NeoGenomics, Inc. has a twelve month low of $12.77 and a twelve month high of $20.94. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99.
NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.05 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.04. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The firm had revenue of $167.80 million during the quarter, compared to analyst estimates of $167.00 million. During the same period last year, the company posted ($0.06) EPS. The business's quarterly revenue was up 10.5% compared to the same quarter last year. Equities analysts anticipate that NeoGenomics, Inc. will post -0.16 EPS for the current year.
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.